These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 15680586)

  • 21. Statistical tools for virtual screening.
    Krumrine JR; Maynard AT; Lerman CL
    J Med Chem; 2005 Nov; 48(23):7477-81. PubMed ID: 16279807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Druggability indices for protein targets derived from NMR-based screening data.
    Hajduk PJ; Huth JR; Fesik SW
    J Med Chem; 2005 Apr; 48(7):2518-25. PubMed ID: 15801841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quest for the rings. In silico exploration of ring universe to identify novel bioactive heteroaromatic scaffolds.
    Ertl P; Jelfs S; Mühlbacher J; Schuffenhauer A; Selzer P
    J Med Chem; 2006 Jul; 49(15):4568-73. PubMed ID: 16854061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. "Bayes affinity fingerprints" improve retrieval rates in virtual screening and define orthogonal bioactivity space: when are multitarget drugs a feasible concept?
    Bender A; Jenkins JL; Glick M; Deng Z; Nettles JH; Davies JW
    J Chem Inf Model; 2006; 46(6):2445-56. PubMed ID: 17125186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design strategies for building drug-like chemical libraries.
    Mitchell T; Showell GA
    Curr Opin Drug Discov Devel; 2001 May; 4(3):314-8. PubMed ID: 11560064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Literature-based generation of hypotheses on chemical composition using database co-occurrence of chemical compounds.
    Milman BL
    J Chem Inf Model; 2005; 45(5):1153-8. PubMed ID: 16180892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determination and mapping of activity-specific descriptor value ranges for the identification of active compounds.
    Eckert H; Bajorath J
    J Med Chem; 2006 Apr; 49(7):2284-93. PubMed ID: 16570925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Library fingerprints: a novel approach to the screening of virtual libraries.
    Klon AE; Diller DJ
    J Chem Inf Model; 2007; 47(4):1354-65. PubMed ID: 17595072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A scoring scheme for discriminating between drugs and nondrugs.
    Sadowski J; Kubinyi H
    J Med Chem; 1998 Aug; 41(18):3325-9. PubMed ID: 9719584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medicinal chemistry tools: making sense of HTS data.
    Kolossov E; Lemon A
    Eur J Med Chem; 2006 Feb; 41(2):166-75. PubMed ID: 16368163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel trends in high-throughput screening.
    Mayr LM; Bojanic D
    Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Data mining a small molecule drug screening representative subset from NIH PubChem.
    Xie XQ; Chen JZ
    J Chem Inf Model; 2008 Mar; 48(3):465-75. PubMed ID: 18302356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can we learn to distinguish between "drug-like" and "nondrug-like" molecules?
    Ajay A; Walters WP; Murcko MA
    J Med Chem; 1998 Aug; 41(18):3314-24. PubMed ID: 9719583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Strategy of molecular drug design: hits, leads and drug candidates].
    Guo ZR
    Yao Xue Xue Bao; 2008 Sep; 43(9):898-904. PubMed ID: 19048779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug and drug candidate building block analysis.
    Wang J; Hou T
    J Chem Inf Model; 2010 Jan; 50(1):55-67. PubMed ID: 20020714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-based maximal affinity model predicts small-molecule druggability.
    Cheng AC; Coleman RG; Smyth KT; Cao Q; Soulard P; Caffrey DR; Salzberg AC; Huang ES
    Nat Biotechnol; 2007 Jan; 25(1):71-5. PubMed ID: 17211405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and validation of in silico models for estimating drug preformulation risk in PEG400/water and Tween80/water systems.
    Crivori P; Morelli A; Pezzetta D; Rocchetti M; Poggesi I
    Eur J Pharm Sci; 2007 Nov; 32(3):169-81. PubMed ID: 17714921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lead optimization via high-throughput molecular docking.
    Joseph-McCarthy D; Baber JC; Feyfant E; Thompson DC; Humblet C
    Curr Opin Drug Discov Devel; 2007 May; 10(3):264-74. PubMed ID: 17554852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neighborhood behavior of in silico structural spaces with respect to in vitro activity spaces-a novel understanding of the molecular similarity principle in the context of multiple receptor binding profiles.
    Horvath D; Jeandenans C
    J Chem Inf Comput Sci; 2003; 43(2):680-90. PubMed ID: 12653538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 'Metabolite-likeness' as a criterion in the design and selection of pharmaceutical drug libraries.
    Dobson PD; Patel Y; Kell DB
    Drug Discov Today; 2009 Jan; 14(1-2):31-40. PubMed ID: 19049901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.